Adjuvant and neoadjuvant systemic therapy for pancreas adenocarcinoma Review uri icon

Overview

MeSH Major

  • Adenocarcinoma
  • Pancreatic Neoplasms

abstract

  • The last two decades of research in the adjuvant setting of pancreas adenocarcinoma have established the value of adjuvant systemic therapy as being able to delay recurrence and increase overall survival. International standards of care in the adjuvant setting include either 6 months of gemcitabine or 5-fluorouracil and leucovorin. The added value of additional agents in the adjuvant setting is being evaluated in several large adjuvant studies. The role of a targeted agent in the adjuvant setting remains investigational. Other major areas of exploration include the integration of adjuvant immunotherapeutic approaches, which provide promise in a setting of micrometastatic disease volumes where such approaches may have greatest value.

publication date

  • January 2015

Research

keywords

  • Review

Identity

Language

  • eng

PubMed Central ID

  • PMC4991774

Digital Object Identifier (DOI)

  • 10.1053/j.seminoncol.2014.12.012

PubMed ID

  • 25726058

Additional Document Info

start page

  • 134

end page

  • 43

volume

  • 42

number

  • 1